Zura Bio Limited (ZURA) Stock

Zura Bio Limited (ZURA) is a Healthcare stock trading at $3.74 (as of 2026-06-18), with a market capitalization of $389.49M and a trailing P/E of -3.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Zura Bio Limited is a clinical-stage biotechnology company developing medicines for immune and inflammatory disorders. Its pipeline includes ZB-168, an inhibitor of IL7Rα, and Torudokimab, a monoclonal antibody that neutralizes IL-33, which is in Phase 2 development.

Valuation — source: SEC EDGAR (first-party)
Price$3.74
Market Cap$389.49M
P/E Ratio-3.8
EV / EBITDA-2.0
Price / Book1.80
Price / Sales66.72
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6.34M
Net Margin-1083.5%
Return on Equity-34.8%
Current Ratio19.33
Revenue Growth (YoY)-27.4%
EPS Growth (YoY)15.8%
FCF Growth (YoY)70.4%
Valuation vs Sector & Industry
Stock P/E-3.8
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-118.0%
vs Industry-122.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSUVRETTA CAPITAL MANAGEMENT, LLC ($53.95M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSandeep C. Kulkarni
Employees30
CountryUS
IPO Date2023-03-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by revenue (market cap unavailable); US-domiciled)

  • Trevi Therapeutics, Inc. (TRVI)
  • Lexeo Therapeutics, Inc. Common Stock (LXEO)
  • Alto Neuroscience, Inc. (ANRO)
  • X4 Pharmaceuticals, Inc. (XFOR)
  • Protara Therapeutics, Inc. (TARA)
  • Cabaletta Bio, Inc. (CABA)
  • Fate Therapeutics, Inc. (FATE)
  • Korro Bio, Inc. (KRRO)
ZURA earnings history · ZURA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.